

**Virginia's Department of Medical Assistance Services  
Pharmacy and Therapeutics Committee Meeting**

*600 East Broad Street – 7<sup>th</sup> Floor Conference Rooms  
Richmond, Virginia 23219*

**Thursday, October 20, 2016 - 10:00 a.m.**

**Welcome and Comments from DMAS' Director**

**Cynthia B. Jones**

**Comments from DMAS' Chief Medical Officer**

**Kate Neuhausen, MD, MPH**

**Call to Order**

**Tim Jennings, PharmD, Chairman**

**Drug Utilization Review (DUR) Board Update**

**Avtar Dhillon, MD, DMAS DUR Board**

**Approval of Minutes From April 28, 2016 Meeting**

**P&T Committee Members**

**PDL Management**

**P&T Committee Members**

• **PDL Phase II – New Drug Review**

- Acne Agents (clindamycin/tretinoin generic for Veltin<sup>®</sup>)
- Analgesics, Long Acting Narcotics (Xtampza<sup>™</sup> ER)
- Antifungals, Topical (oxiconazole - generic for Oxistat<sup>®</sup>)
- Antivirals Hepatitis C (Epclusa<sup>®</sup> & Viekira XR<sup>™</sup>)
- Antimigraine Agents, Triptans (Onzetra<sup>™</sup>, Xsail<sup>™</sup>, Zembrace<sup>™</sup>, SymTouch<sup>™</sup>, frovatriptan, Migranow<sup>®</sup> Kit)
- Cytokine & Cam Antagonists (Taltz<sup>®</sup>)
- Diabetes Hypoglycemics Alpha-Glucosidase Inhibitors (miglitol - generic for Glyset<sup>®</sup>)
- Diabetes Hypoglycemics Incretin Mimetics/Enhancers (Jentadueto XR<sup>®</sup>, alogliptin - generic for Nesina<sup>®</sup>, alogliptin/metformin - generic for Kazano<sup>®</sup>, alogliptin/pioglitazone - generic for Oseni<sup>®</sup>)
- Multiple Sclerosis (Zinbryta<sup>™</sup>)
- Nonsteroidal Anti-Inflammatory Drugs (diclofenac 1% gel - generic for Voltaren<sup>®</sup>, Xrylix<sup>®</sup> Kit, Vopac<sup>®</sup> MDS)
- Otic Antibiotics (Otovel)
- Stimulants and Related Agents (Adzenys XR ODT<sup>™</sup> & armodafinil - generic for Nuvigil<sup>®</sup>)

• **PDL Phase I – Annual Review**

**Antibiotic-Anti-Infective**

- Antibiotics, Vaginal

**Blood Modifiers**

- Bile Salts
- Phosphate Binders

**Cardiac Medications**

- Angiotensin Modulators (*ACEs, ARBs, & combination products*)
- Angiotensin Modulators II (*Direct Renin Inhibitors & combination products*)
- Antihypertensives, Sympatholytics
- Beta Blockers (*includes combination products*)
- Calcium Channel Blockers (*includes dihydropyridine and non-dihydropyridine agents*)
- Lipotropics, Others (*includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agents, Fibrin Acid derivatives, Microsomal Triglyceride Transfer Protein Inhibitors, Niacin derivatives, Oligonucleotide Inhibitors and Omega 3 agents*)
- Lipotropics, Statins
- Pulmonary Hypertension Agents (*Endothelin-1 agents, PDE-5 Inhibitors; Prostacyclin analogues, Prostacyclin Vasodilators, Soluble Guanylate Cyclase Stimulators*)

### **Central Nervous System**

- Alzheimer's Agents
- Anticonvulsants
- Antidepressants
- Antidepressants, SSRI
- Antipsychotics
- Sedative Hypnotics (*includes other Hypnotics*)

### **Dermatologic Agents**

- Immunological Atopic Dermatitis
- Steroids, Topical

### **Endocrine & Metabolic Agents**

- Glucocorticoids, Oral
- Growth Hormones
- Hereditary Angioedema (HAE)
- Progestins for Cachexia

### **Gastrointestinal**

- Antiemetic/Antivertigo Agents
- Gastrointestinal (GI) Motility, Chronic
- H. Pylori Treatment
- Histamine-2 Receptor Antagonists (H-2RA)
- Proton Pump Inhibitors
- Ulcerative Colitis (*oral and rectal*)

### **Genitourinary**

- BPH Agents (*includes Alpha Blockers, Androgen Hormone Inhibitors and Phosphodiesterase (PDE) 5 Inhibitors for BPH treatment*)
- Bladder Relaxants

### **Ophthalmics**

- Allergic Conjunctivitis (*includes Ophthalmic Antihistamines & Mast Cell Stabilizers*)
- Antibiotics
- Antibiotic/Steroid Combinations
- Anti-Inflammatory Agents (*includes Ophthalmic NSAIDS & Corticosteroids*)
- Glaucoma Agents (*includes Alpha-2 Adrenergics, Beta-blockers, Carbonic Anhydrase Inhibitors, Prostaglandin Inhibitors*)

### **Respiratory**

- Anti-Allergens, Oral
- Antibiotics, Inhaled
- Antihistamines Minimally Sedating
- Bronchodilators, Long Acting Beta Adrenergics
- Bronchodilators, Short Acting Beta Adrenergics
- COPD (*includes Anticholinergics, Bronchodilators and Phosphodiesterase 4 (PDE4) Inhibitors*)
- Cough & Cold Agents (Legend)
- Epinephrine, Self-Injected
- Glucocorticoids (*includes nebulized solutions, metered dose inhalers and combinations*)
- Intranasal Rhinitis (*includes Antihistamines and Corticosteroids*)
- Leukotriene Modifiers

**Confidential Meeting (Pricing Information Discussion)**

**P&T Committee, DMAS & PS Staff  
Pursuant to 42 USC §1396r-8**

**PDL Recommendations and Vote**

**P&T Committee Members**

**Criteria Discussion of Phase II New Drugs\***

**P&T Committee Members**

**Criteria Discussion of PDL Phase I Drug Classes\***

**P&T Committee Members**

**Next Meeting – April 21, 2017**

**Tim Jennings, Pharm. D., Chairman**

*\*Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

**Oral Presentations:** The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes in Phase I which are scheduled for review at the October meeting and new drugs in PDL Phase II listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase I Annual Reviews – October 2015 to present
- New Drugs in PDL Phase I or II Drug Classes – October 2014 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send requested information to [pdlinput@dm.virginia.gov](mailto:pdlinput@dm.virginia.gov) and [dfmoody@magellanhealth.com](mailto:dfmoody@magellanhealth.com) by 5 p.m. EST on **Thursday, September 22, 2016.**

**Written information/comments:** The P&T Committee will also accept written comments for consideration. Please send statements to [pdlinput@dm.virginia.gov](mailto:pdlinput@dm.virginia.gov) by 5 p.m. EST **Thursday, September 22, 2016.**